In vivo B7-H3 CAR-T cells for pancreatic cancer therapy
Official title: SBIR: In vivo engineering of multifaceted B7H3.CAR-T cells for cellular immunotherapy of pancreatic ductal adenocarcinoma
Funded at Mucommune, LLC · NIH-11416630 · Data updated 2026-11-12
A patient-friendly look at a new approach that aims to produce CAR-T cells directly inside the body to target pancreatic cancer.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mucommune, LLC NIH-funded |
| Lab location | 1 site (Morrisville, UNITED STATES) |
| Project start | September 16, 2025 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,146,083 |
| NIH project number | 5R44CA310402-02 |
| Project ID | NIH-11416630 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients with pancreatic ductal adenocarcinoma who are eligible for cellular immunotherapy and can tolerate investigational gene-delivery treatment.
✕Less likely to help
Patients whose cancer biology does not respond to B7-H3 targeting or who cannot undergo gene-delivery therapies may not benefit.
What this research studies
This project explores a way to rewrite a patient’s own T-cells so they can seek out and kill pancreatic cancer cells without the lengthy lab steps. It uses a specialized delivery system to introduce CAR-T instructions directly into the body, potentially speeding up treatment and reducing costs. The team has already shown in early studies that this approach can target B7-H3 and eliminate cancer in animal models, with a focus on solid tumors like pancreatic cancer. If successful, this could shorten time to treatment and improve how well CAR-T therapy works for tough pancreatic tumors.
Why it matters
Potential benefit: If successful, patients may receive a faster, potentially more affordable CAR-T therapy that specifically targets pancreatic cancer cells.
How similar studies have gone: Preclinical work has shown promising in vivo targeting and tumor destruction, but clinical results in humans are still needed.
Where this research is happening
-
Mucommune, LLC
Morrisville, United States Active
Researchers
- Principal investigator: Yang, Ming — Mucommune, LLC
- Study coordinator: Yang, Ming
Related research
Other NIH-funded projects on the same topics.
-
Novel combo therapy using oncolytic adenovirus and immune drugs for pancreatic cancer
Aims to combine an oncolytic virus with immune therapies to help shrink pancreatic tumors before surgery and keep them from coming back.
-
Combining a targeted tumor‑ablation technique with immunotherapy for pancreatic cancer
Seeing if pairing irreversible electroporation (a focused tumor‑destroying procedure) with immune‑boosting drugs can help people with pancreatic ductal adenocarcinoma respond better to treatment.
-
Understanding how immunotherapy works in pancreatic cancer
This study is looking at why some people with pancreatic cancer benefit from immunotherapy while others don’t, and it aims to find better treatment combinations that can help boost the immune system's fight against this tough cancer.
-
Using electrical pulses to enhance cancer immunotherapy for pancreatic cancer
This study is looking at how using electrical pulses to destroy pancreatic cancer cells, along with immune therapy, might help make the cancer more responsive to treatment and improve survival for patients with pancreatic ductal adenocarcinoma.
-
Fibrin-rich tumor stroma as a new driver of immune response in pancreatic cancer
This grant explores how fibrin-involved tumor surroundings in pancreatic cancer might affect immune therapy, with the goal of making treatments work better for patients.
-
TREM2+ macrophages and liver metastases in pancreatic cancer
Researchers are studying immune cells in liver metastases from pancreatic cancer to understand how they influence the cancer’s spread and more effective treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.